CLEC9A Protein (AA 57-264) (Fc Tag)

Produktnummer ABIN7274367

Produktdetails

Target: CLEC9A (C-Type Lectin Domain Family 9, Member A (CLEC9A))

Protein-Typ: Recombinant

Proteineigenschaft: AA 57-264

Spezies: Maus

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses CLEC9A Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Mouse CLEC9A Protein

Sequenz: Lys57-Ile264

Produktmerkmale: Recombinant Mouse CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Ile264.

Reinheit: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: CLEC9A (C-Type Lectin Domain Family 9, Member A (CLEC9A))

Andere Bezeichnung: CLEC9A (CLEC9A Produkte)

Synonyme: 9830005G06Rik Protein, DNGR-1 Protein, DNGR1 Protein, UNQ9341 Protein, RGD1562513 Protein, C-type lectin domain family 9, member a Protein, C-type lectin domain containing 9A Protein, C-type lectin domain family 9, member A Protein, Clec9a Protein, CLEC9A Protein

Hintergrund: CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.

Molekulargewicht: 50.9 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.

NCBI Accession: NP_001192292